Liafensine is under clinical development by Denovo Biopharma and currently in Phase II for Treatment Resistant Depression. According to GlobalData, Phase II drugs for Treatment Resistant Depression have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Liafensine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Liafensine (BMS-820836) is under development for the treatment of treatment-resistant depression. BMS-820836 is administered orally. The drug candidate is a small molecule synthetic product. The drug candidate is a triple re uptake inhibitor targeting norepinephrine, serotonin and dopamine. It was also under development for treatment resistant major depression and major depressive disorder.
Denovo Biopharma overview
Denovo Biopharma, formerly Denovo Biomarkers is a biotechnology company that provides novel biomarker solutions to personalize drug development. The company enables drug developers to design new clinical trials in targeted patient populations and re-evaluates medicines that failed in general patient populations. Its core technology performs genomic biomarker discovery using archived clinical samples. Denovo Biopharma supports its partners throughout the evolution process up to the approval and launch of the drug together with the companion diagnostic test. The company also partners with life science companies and drug developers. It has operations in the US and China. Denovo Biopharma is headquartered in San Diego, California, the US.
For a complete picture of Liafensine’s drug-specific PTSR and LoA scores, buy the report here.